This price target is based on 0 analysts offering 12 month price targets for Concepta PLC (CPT.L) in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.
The current consensus among 0 contributing investment analysts is to n/a stock in Concepta PLC (CPT.L). This N/A consensus rating has held steady for over two years.
Concepta PLC, a women's healthcare company, develops and commercializes mobile health diagnostics medical devices in the United Kingdom. Its products help women with unexplained infertility to concieve. The company offers MYLO, a home-use personalized fertility tracking and pregnancy self-testing system. MYLO allows quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone during ovulation and human chorionic gonadotropin hormone level during pregnancy, facilitating conception rates and early diagnosis of fertility issues. The company was formerly known as Frontier Resources International PLC. Concepta PLC was incorporated in 2008 and is based in Cardiff, the United Kingdom.